VTRS Q2 2022 Earnings — Viatris Inc. Revenue & Financial Results | Market Cap Arena

VTRSViatris Inc.

$17B

Q2 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.1B-10.1% YoY

Gross Profit

$1.7B41.4% margin

Operating Income

$549M13.3% margin

Net Income

$314M7.6% margin

EPS (Diluted)

$0.26

QoQ Revenue Growth

-1.8%

Cash Flow

Operating Cash Flow

$803M

Free Cash Flow

$713M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$51.1B

Total Liabilities

$31.3B

Stockholders' Equity

$19.8B

Cash & Equivalents

$665M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.1B	$4.6B	-10.1%
Gross Profit	$1.7B	$1.3B	+28.3%
Operating Income	$549M	-$48M	+1247.9%
Net Income	$314M	-$279M	+212.4%

Revenue Segments

Brands

$2.5B60%

Generics

$1.3B31%

Complex GX and Biosimilars

$355M9%

Geographic Segments

Developed Markets Segment

$2.5B60%

Emerging Markets Segment

$651M16%

Greater China Segment

$548M13%

Japan, Australia and New Zealand Segment

$427M10%